Developer docs
API playgroundTry for free, no card

Search company profiles

Small Pharma

Full company profile

uuid005bw62

Namestring
Small Pharma
Legal namestring
Helus Pharma
Websiteurl
smallpharma.com
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Helus Pharma (formerly Small Pharma, founded 2015) is a clinical-stage biopharmaceutical company headquartered in London, UK, developing next-generation therapies for mental health conditions through a proprietary platform of novel serotonergic agonists (NSAs). Its core technology consists of synthetic molecules engineered to activate serotonin pathways believed to promote neuroplasticity, paired with novel delivery formulations intended to reduce inter-individual variability in acute effects and shorten clinic time. The pipeline is led by CYB004, currently in Phase 2 trials for Generalized Anxiety Disorder following completed enrollment, alongside two additional lead programs, HLP003 and HLP004. The intended end customers are patients with treatment-resistant mental health conditions — primarily anxiety disorders and major depressive disorder — who would access the therapy through prescription pharmaceutical channels upon regulatory approval.

The business model is a traditional clinical-stage biotech GTM: advance candidates through clinical trials to FDA approval, then commercialize via prescription-based pharmaceutical distribution (pharmacies, hospitals, healthcare providers). The company is explicitly pre-revenue, with no commercialized products and no disclosed pricing; revenue mechanics will be one-time prescription drug sales following approval. Intellectual property is the primary non-pipeline asset, with 350+ pending patent applications and 100+ granted patents covering the NSA platform and delivery formulations. The company is publicly traded on NASDAQ and CBOE Canada under ticker HELP, providing capital-markets funding access in lieu of product revenue.

Leadership includes newly appointed CEO Michael Halstead, Co-Founder and Executive Chairman Eric So (previously interim CEO), Chief Medical Officer Amir Inamdar, Chief Scientific Officer Alex Nivorozhkin, and Scientific Advisory Committee Chair Freda Lewis-Hall. Scientific leadership's cited credentials — experience overseeing 60+ IND programs and developing 10+ blockbuster drugs — reflect prior industry experience rather than Helus Pharma's internal commercial track record, which is nonexistent given its pre-revenue status. Operations are described via firmographics as a small team (~11 employees), though the breadth of clinical programs and dual-exchange listing imply a broader operational footprint than this headcount suggests.

Short descriptiontext

Helus Pharma (formerly Small Pharma) is a pre-revenue, London-based clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead candidate CYB004 in Phase 2 trials for Generalized Anxiety Disorder and publicly listed on NASDAQ under HELP.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
psychedelic therapeutics, mental health treatments, novel serotonergic agonists, clinical-stage biopharmaceutical, neuropsychiatric drug development
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuropsychiatric Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales (Future)
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue expected to be generated from commercialized prescription drugs following successful clinical trials and regulatory approvals. Current drug programs include CYB004 (Phase 2 for Generalized Anxiety Disorder), HLP003, and HLP004.

helus.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Small Pharma is a clinical-stage biopharmaceutical company that discovers and develops novel serotonergic agonists (NSAs) for the treatment of mental health conditions. Its lead programs — HLP003 (targeting depression) and HLP004 (targeting anxiety) — leverage proprietary novel formulation technology designed to enable alternative delivery routes such as subcutaneous and inhaled administration, aiming to improve patient experience and accessibility over traditional psychedelic therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Completed enrollment in Phase 2 study evaluating CYB004 for Generalized Anxiety Disorder
Product overview1 text field

Helus Pharma is a pharmaceutical company pioneering next-generation mental health therapies through a proprietary drug development platform that creates novel serotonergic agonists. The company's portfolio includes two lead drug programs (HLP003 and HLP004), with CYB004 currently in Phase 2 trials for Generalized Anxiety Disorder. Their technology platform focuses on synthetic molecules designed to activate serotonin pathways to promote neuroplasticity.

Product and service1 record
1HLP003
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Commercial-stage CNS company with FDA-approved Auvelity for depression and additional pipeline assets. Comparable as a CNS-focused company with novel-mechanism therapies targeting depression and other mental health conditions, providing a useful proxy for what a successful Helus Pharma could look like at commercialization.

TypeBroad incumbent
Description

Established CNS-focused biopharma with FDA-approved Zurzuvae for postpartum depression and pipeline in depression/epilepsy. Comparable as a more advanced CNS biotech with novel-mechanism therapies, similar regulatory pathway experience, and overlapping mental health target indications.

TypeDirect peer
Description

Clinical-stage company developing novel serotonergic-based therapies (specifically mebufotenin and other 5-HT2A agonists) for depression. Highly comparable as a publicly-traded biotech pursuing serotonergic mechanisms for treatment-resistant depression with Phase 2/3 assets.

4ATAI Life Sciences
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable platform-company model with multiple programs in mental health, similar trial-stage assets, and overlapping target indications like depression and anxiety.

TypeBroad incumbent
Description

Global pharmaceutical company with established mental health franchise including Spravato (esketamine) for treatment-resistant depression. Comparable as a key competitor and potential acquirer/partner, with deep commercial infrastructure in mental health and experience launching clinic-administered CNS therapies.

6MindMed
TypeDirect peer
Description

Clinical-stage psychedelic medicine company developing novel therapies for anxiety, depression, and ADHD. Comparable as a publicly-traded CNS biotech with multiple serotonergic-pathway programs in clinical development targeting similar mental health indications.

TypeBroad incumbent
Description

Major pharmaceutical company with extensive mental health portfolio including Cymbalta, Prozac, and emerging depression therapies. Comparable as a broad incumbent that defines the competitive landscape in mental health and serves as both a potential partner and primary competitive threat.

TypeDirect peer
Description

Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Highly comparable to Helus Pharma as another publicly-listed CNS biotech pursuing novel-mechanism therapies with psychedelic-adjacent mechanisms, Phase 2/3 assets, and similar GTM motion targeting FDA approval.

TypeDirect peer
Description

Clinical-stage psychedelic therapeutics company with multiple programs in depression and anxiety. Comparable publicly-listed CNS biotech with similar mechanism work, pipeline approach, and target indications. Notably, Cybin acquired Small Pharma (whose firmographic footprint appears in the dataset).

TypeBroad incumbent
Description

Global pharmaceutical company with established CNS franchise including previous SSRI/SNRI products and active interest in mental health pipeline assets. Comparable as a potential strategic acquirer with deep CNS commercial capabilities and resources to in-license or acquire novel-mechanism mental health therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Small Pharma

Neuropsychiatric Pharmaceuticalssmallpharma.com

Helus Pharma (formerly Small Pharma) is a pre-revenue, London-based clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead candidate CYB004 in Phase 2 trials for Generalized Anxiety Disorder and publicly listed on NASDAQ under HELP.

What Small Pharma does

Helus Pharma (formerly Small Pharma, founded 2015) is a clinical-stage biopharmaceutical company headquartered in London, UK, developing next-generation therapies for mental health conditions through a proprietary platform of novel serotonergic agonists (NSAs). Its core technology consists of synthetic molecules engineered to activate serotonin pathways believed to promote neuroplasticity, paired with novel delivery formulations intended to reduce inter-individual variability in acute effects and shorten clinic time. The pipeline is led by CYB004, currently in Phase 2 trials for Generalized Anxiety Disorder following completed enrollment, alongside two additional lead programs, HLP003 and HLP004. The intended end customers are patients with treatment-resistant mental health conditions — primarily anxiety disorders and major depressive disorder — who would access the therapy through prescription pharmaceutical channels upon regulatory approval.

The business model is a traditional clinical-stage biotech GTM: advance candidates through clinical trials to FDA approval, then commercialize via prescription-based pharmaceutical distribution (pharmacies, hospitals, healthcare providers). The company is explicitly pre-revenue, with no commercialized products and no disclosed pricing; revenue mechanics will be one-time prescription drug sales following approval. Intellectual property is the primary non-pipeline asset, with 350+ pending patent applications and 100+ granted patents covering the NSA platform and delivery formulations. The company is publicly traded on NASDAQ and CBOE Canada under ticker HELP, providing capital-markets funding access in lieu of product revenue.

Leadership includes newly appointed CEO Michael Halstead, Co-Founder and Executive Chairman Eric So (previously interim CEO), Chief Medical Officer Amir Inamdar, Chief Scientific Officer Alex Nivorozhkin, and Scientific Advisory Committee Chair Freda Lewis-Hall. Scientific leadership's cited credentials — experience overseeing 60+ IND programs and developing 10+ blockbuster drugs — reflect prior industry experience rather than Helus Pharma's internal commercial track record, which is nonexistent given its pre-revenue status. Operations are described via firmographics as a small team (~11 employees), though the breadth of clinical programs and dual-exchange listing imply a broader operational footprint than this headcount suggests.

Small Pharma firmographics

Firmographics
Name
Small Pharma
Legal name
Helus Pharma
Website
https://smallpharma.com
Company type
Public
Operating status
Operating
Headcount range
1–10 employees
Short description
Helus Pharma (formerly Small Pharma) is a pre-revenue, London-based clinical-stage biotech developing novel serotonergic agonist therapies for mental health conditions, with lead candidate CYB004 in Phase 2 trials for Generalized Anxiety Disorder and publicly listed on NASDAQ under HELP.
Ownership category
akta.pro rank

Small Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Drug Sales (Future): Pre-revenue clinical-stage biopharmaceutical company. Revenue expected to be generated from commercialized prescription drugs following successful clinical trials and regulatory approvals. Current drug programs include CYB004 (Phase 2 for Generalized Anxiety Disorder), HLP003, and HLP004.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Small Pharma product offering

Product offering

Core offering

Small Pharma is a clinical-stage biopharmaceutical company that discovers and develops novel serotonergic agonists (NSAs) for the treatment of mental health conditions. Its lead programs — HLP003 (targeting depression) and HLP004 (targeting anxiety) — leverage proprietary novel formulation technology designed to enable alternative delivery routes such as subcutaneous and inhaled administration, aiming to improve patient experience and accessibility over traditional psychedelic therapies.

Product overview

Helus Pharma is a pharmaceutical company pioneering next-generation mental health therapies through a proprietary drug development platform that creates novel serotonergic agonists. The company's portfolio includes two lead drug programs (HLP003 and HLP004), with CYB004 currently in Phase 2 trials for Generalized Anxiety Disorder. Their technology platform focuses on synthetic molecules designed to activate serotonin pathways to promote neuroplasticity.

Differentiator

Problem solved

Functional benefit

Products and services

  • HLP003

Quantifiable outcome

  • Completed enrollment in Phase 2 study evaluating CYB004 for Generalized Anxiety Disorder

Companies that use Small Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Small Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Small Pharma partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Small Pharma competitors and assessment

Company assessment

Emerging players

  • Axsome Therapeutics: Commercial-stage CNS company with FDA-approved Auvelity for depression and additional pipeline assets. Comparable as a CNS-focused company with novel-mechanism therapies targeting depression and other mental health conditions, providing a useful proxy for what a successful Helus Pharma could look like at commercialization.

Broad incumbents

  • Sage Therapeutics: Established CNS-focused biopharma with FDA-approved Zurzuvae for postpartum depression and pipeline in depression/epilepsy. Comparable as a more advanced CNS biotech with novel-mechanism therapies, similar regulatory pathway experience, and overlapping mental health target indications.
  • Johnson & Johnson: Global pharmaceutical company with established mental health franchise including Spravato (esketamine) for treatment-resistant depression. Comparable as a key competitor and potential acquirer/partner, with deep commercial infrastructure in mental health and experience launching clinic-administered CNS therapies.
  • Eli Lilly: Major pharmaceutical company with extensive mental health portfolio including Cymbalta, Prozac, and emerging depression therapies. Comparable as a broad incumbent that defines the competitive landscape in mental health and serves as both a potential partner and primary competitive threat.
  • Pfizer: Global pharmaceutical company with established CNS franchise including previous SSRI/SNRI products and active interest in mental health pipeline assets. Comparable as a potential strategic acquirer with deep CNS commercial capabilities and resources to in-license or acquire novel-mechanism mental health therapies.

Direct peers

  • GH Research: Clinical-stage company developing novel serotonergic-based therapies (specifically mebufotenin and other 5-HT2A agonists) for depression. Highly comparable as a publicly-traded biotech pursuing serotonergic mechanisms for treatment-resistant depression with Phase 2/3 assets.
  • ATAI Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and complementary therapies for mental health. Comparable platform-company model with multiple programs in mental health, similar trial-stage assets, and overlapping target indications like depression and anxiety.
  • MindMed: Clinical-stage psychedelic medicine company developing novel therapies for anxiety, depression, and ADHD. Comparable as a publicly-traded CNS biotech with multiple serotonergic-pathway programs in clinical development targeting similar mental health indications.
  • Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Highly comparable to Helus Pharma as another publicly-listed CNS biotech pursuing novel-mechanism therapies with psychedelic-adjacent mechanisms, Phase 2/3 assets, and similar GTM motion targeting FDA approval.
  • Cybin Inc. Clinical-stage psychedelic therapeutics company with multiple programs in depression and anxiety. Comparable publicly-listed CNS biotech with similar mechanism work, pipeline approach, and target indications. Notably, Cybin acquired Small Pharma (whose firmographic footprint appears in the dataset).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Small Pharma social profiles

Digital presence

Small Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Small Pharma leadership team

Management profile

Number of profiles

Profiles4 records

Small Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Small Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Small Pharma

What does Small Pharma do?

Small Pharma is a clinical-stage biopharmaceutical company that discovers and develops novel serotonergic agonists (NSAs) for the treatment of mental health conditions. Its lead programs — HLP003 (targeting depression) and HLP004 (targeting anxiety) — leverage proprietary novel formulation technology designed to enable alternative delivery routes such as subcutaneous and inhaled administration, aiming to improve patient experience and accessibility over traditional psychedelic therapies.

Is Small Pharma a public or private company?

Small Pharma is a public company. It is classified as public and is currently operating.

When was Small Pharma founded?

Small Pharma was founded in -1. It employs 1 to 10 people.

How does Small Pharma make money?

One revenue line is on record: pharmaceutical Drug Sales (Future).

Who are Small Pharma's main competitors?

Axsome Therapeutics is listed as an emerging player. Broad incumbents are Sage Therapeutics, Johnson & Johnson, Eli Lilly and Pfizer. Direct peers are GH Research, ATAI Life Sciences, MindMed, Compass Pathways and Cybin Inc..

Does Small Pharma have an API?

No public API is recorded for Small Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals